ArticleMolecular pharmaceutics2026
Mechanism of Self-Assembly of the Gonadropin Releasing Hormone Antagonist Teverelix into Amyloid Fibrils.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Teverelix is a short non-natural peptide, which is a gonadotropin releasing hormone antagonist and used as a treatment for prostate cancer. Teverelix is formulated as a trifluoroacetic acid salt, which, at the high concentrations used for parenteral injection, forms a microcrystalline suspension. At low concentrations and immediately after injection, teverelix self-assembles into a fibrillar species thought to be important for the slow-release kinetics and long-acting action of this peptide in vivo. In this paper, we confirmed the amyloid-like identity of teverelix fibrils using X-ray fiber diffraction and transmission electron microscopy. The inter-β-sheet packing distance was found to be larger than that of typical amyloid fibrils and this was attributed to the large non-natural side chains within the peptide. Using data from numerous biophysical experiments, a model of the structure of teverelix within the fibril is proposed. The kinetics of fibril formation were investigated using standard ThT assays, and teverelix found to fibrillate rapidly over a wide range of conditions. The fibrillation rate was shown to depend critically upon pH, peptide, and trifluoroacetic acid concentration. Fibrillation was accompanied by a drop in pH, which we attribute to the fact that the pyridinium side chain must be deprotonated before self-assembly. Based on our results, we propose a nucleation-polymerization mechanism in which dimers of teverelix rapidly self-assemble into amyloid-like fibrils with little change in the secondary structure but burial of some of the aromatic acid side chains. Interestingly, the fibrils can, under certain conditions, align to create a highly ordered array. To the best of our knowledge, this is the first paper studying teverelix in detail from a biophysical perspective, and it is directly relevant to the aggregation of the peptide observed in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.